Developer docs
API playgroundTry for free, no card

Search company profiles

Insilico Medicine

Full company profile

uuid00000km

Namestring
Insilico Medicine
Legal namestring
InSilico Medicine
Websiteurl
insilico.com
Company typeenum
Public
Founded yearint
2014
Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI drug discovery, generative chemistry platform, target identification software, clinical trial prediction, biologics design platform
Industry5 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Laboratory Analytical Instruments3826
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
Product category
AI Drug Discovery Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1Software Licensing (Pharma.AI platform)
TypeSubscription Recurring
Description

Subscription and licensing revenue from Pharma.AI platform products (PandaOmics, Chemistry42, Generative Biologics, inClinico) licensed to pharmaceutical and biotech companies; more than 40 pharmaceutical companies use Insilico's technology.

insilico.com
2Drug Discovery Collaboration Deals (Upfront + Milestones)
TypeLicensing Royalties
Description

Large milestone-driven deals with pharma partners combining upfront payments (e.g., $115M from Eli Lilly, $80M from Exelixis), R&D funding, and milestone payments tied to development/regulatory/commercial progress (e.g., Eli Lilly up to $2.75B total, Sanofi up to $1.2B, SK Biopharmaceuticals up to $2.5B+, Servier $888M).

intuitionlabs.ai
3Royalties on Net Sales
TypeLicensing Royalties
Description

Tiered royalties on future net sales of products arising from collaborations, including single-digit royalties (e.g., SK Biopharmaceuticals deal) and tiered royalties (Eli Lilly deal).

intuitionlabs.ai
4Co-development Revenue (Pipeline Programs)
TypeProfessional Services
Description

Revenue from co-developed programs with shared global rights (e.g., Hygtia Therapeutics 50/50 co-development of ISM8969), where Insilico is eligible for upfront and milestone payments as the program advances (up to $66M for Hygtia program).

insilico.com
5Grants and Non-dilutive Funding
TypeSubscription Recurring
Description

Non-dilutive funding including the Bill & Melinda Gates Foundation grant ($700K+) for contraceptive design and other research grants.

bioengineer.org
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Enterprise licensing — quote-based, milestone-driven
ModelOtherBilling cadenceMulti-year contract
Notes

Upfront payments, R&D funding, development/regulatory/commercial milestones, and tiered royalties — all negotiated per deal (typical total deal values range from hundreds of millions to $2.75B)

intuitionlabs.ai
2Pharma.AI platform software — quote-based subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Subscription pricing not publicly disclosed; platform access negotiated with pharmaceutical and biotech customers.

insilico.com
3MMAI Gym — 3-month training subscription
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Subscribe for a 3-month training session to improve a model's drug discovery fitness levels.

insilico.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 9 records shown
1Pharma.AI
Description

End-to-end generative AI software platform for drug discovery, scientific research and sustainability, encompassing Biology42, Chemistry42, and Medicine42.

insilico.com
+8 more records
Core offering1 text field

Insilico Medicine develops and commercializes Pharma.AI, an end-to-end generative AI software platform for drug discovery, with modules spanning biology (Biology42: PandaOmics, Generative Biologics, PreciousGPT), chemistry (Chemistry42), and clinical medicine (Medicine42: inClinico, Nach01), plus Science42: DORA LLM research assistant and MMAI Gym. The company also operates an internal pipeline of 30+ AI-discovered and AI-designed drug candidates and licenses/co-develops them with global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Insilico Medicine is a global, clinical-stage, end-to-end generative AI-driven biotech offering a unified platform-plus-modules product architecture. The core platform is Pharma.AI, a commercially available end-to-end generative AI software suite spanning biology, chemistry, and clinical medicine, organized into three families: Biology42 (PandaOmics for AI target and biomarker discovery, with PandaOmics Box as an alternate packaging), Generative Biologics for biologics design, and PreciousGPT under the "Large Language of Life Models (LLLMs)" umbrella; Chemistry42 for generative small-molecule design, retrosynthesis, ADMET prediction, and molecule optimization; and Medicine42, which includes inClinico for AI-driven Phase II clinical trial outcome prediction and Nach01. Layered on top is the MMAI Gym, a service introduced in January 2026 for training and benchmarking large language models on drug discovery tasks, plus the newly announced LabClaw automation system. Complementing the platform, Insilico operates a fully automated robotics laboratory (Life Star, Suzhou) and an Abu Dhabi Generative AI and Quantum Computing R&D Center, and runs a diversified internal drug pipeline of more than 30 AI-discovered/AI-designed preclinical and clinical programs led by INS018_055/Rentosertib (TNIK inhibitor for IPF).

Product and service11 records
1Pharma.AI Suite
2PandaOmics
CategoryTarget and biomarker discovery software
Description

Generative AI software for therapeutic target and biomarker discovery with 20+ AI and bioinformatics models, transformer-based NLP knowledge graph of biomedical literature, and ChatPandaGPT natural-language querying. Sold to pharmaceutical and biotech researchers.

3Chemistry42
CategoryGenerative chemistry software
Description

Generative chemistry platform integrating 40+ generative models (including autoencoders and GANs) with computational and medicinal chemistry methods to generate and optimize drug-like small molecules; supports structure-based and ligand-based design with AlphaFold integration. Sold to pharmaceutical and biotech researchers.

4Generative Biologics
CategoryBiologics design software
Description

Generative AI platform module for designing therapeutic biologics including therapeutic proteins and antibody candidates, sold as part of the Pharma.AI suite.

5inClinico
CategoryClinical trial prediction software
Description

Generative AI platform that uses a multimodal forecast (small-molecule chemical properties, transcriptomics, text, and clinical trial protocols) to predict Phase II to Phase III clinical trial transition probability. Sold to pharmaceutical and biotech customers.

6Science42: DORA
CategoryLLM research assistant
Description

Draft Outline Research Assistant workflow built on Insilico's Science42 large language model platform, supporting AI-assisted scientific literature drafting, target discovery research, and pharmaceutical R&D workflows.

7Nach01
CategoryMedicine42 platform application
Description

Generative AI application under the Medicine42 suite of Pharma.AI, listed in the platform navigation.

8PreciousGPT
CategoryBiomedical foundation model
Description

Large Language of Life Models (LLLMs) generative AI offering under the Pharma.AI umbrella, presented alongside other LLM-based tools.

9MMAI Gym
CategoryLLM training service
Description

Multi-Modal AI Gym — a service/training platform for LLM developers that offers 3-month training subscriptions to improve model drug discovery fitness and access to CSI/BSI Pharmaceutical Super Intelligence models.

10LabClaw
CategoryDrug discovery automation system
Description

Intelligent automation system intended to advance drug discovery from automation to autonomy, integrating with the Suzhou Life Star robotics laboratory and the broader MMAI Gym ecosystem.

11INS018_055 / Rentosertib (ISM001-055)
CategoryDrug pipeline candidate (IPF)
Description

Lead clinical-stage small-molecule TNIK inhibitor designed by Insilico's generative AI for an AI-discovered target, for idiopathic pulmonary fibrosis (IPF) and kidney fibrosis; the first AI-discovered and AI-designed drug to enter Phase II trials. Available for licensing/co-development with pharmaceutical partners.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage AI-driven drug discovery company combining high-throughput wet-lab biology with machine learning across target identification, hit generation, and translational research — directly comparable end-to-end generative-AI-for-drugs model with partnered pipeline.

TypeDirect peer
Description

Pioneer in AI-driven small-molecule design with a partnered pipeline (e.g., DSP-1181 with Sumitomo, BMS collaborations) using generative chemistry and active learning — directly comparable generative chemistry platform and pharma partnership GTM.

TypeDirect peer
Description

Physics-based computational chemistry and AI-driven molecular simulation platform with both a software business (licensed to pharma/biotech) and an internal drug pipeline — closely comparable hybrid software-plus-pipeline business model.

4Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company building on DeepMind's AlphaFold with partnered programs including a $3B+ collaboration with Novartis and a $1.7B Eli Lilly deal — directly comparable in scaling AI platform deals with Big Pharma.

TypeDirect peer
Description

AI-plus-robotics drug discovery company combining quantum physics, ML, and automated labs with a large pharma partnership base (e.g., Pfizer) — directly comparable as a Greater-China-based, end-to-end AI drug discovery platform with similar GTM.

TypeDirect peer
Description

AI-driven drug discovery company with target identification and clinical pipeline assets (e.g., baricitinib repurposing), using biomedical knowledge graphs and ML — directly comparable target-discovery-plus-platform GTM.

TypeEmerging player
Description

AI-enabled antibody discovery platform with pharma partnerships (e.g., Eli Lilly for COVID antibodies) and an internal biologics pipeline — comparable as a tech-forward biologics discovery company with similar pharma licensing GTM.

TypeEmerging player
Description

Precision medicine company using computational/motion-based drug design to develop targeted oncology therapies (e.g., RLY-4008) — comparable motion-based generative design approach applied to a focused clinical pipeline.

TypeEmerging player
Description

Generative biology company (Flagship-founded) using ML to design de novo protein therapeutics including antibodies and peptides — directly comparable Generative Biologics-like capabilities to Insilico's biologics module.

TypeEmerging player
Description

AI small-molecule discovery company using convolutional neural networks for structure-based design with multi-target pharma partnerships (e.g., Sanofi, Bayer) — comparable AI drug discovery GTM via partnership deals with major pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors40 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Insilico Medicine

AI Drug Discovery Softwareinsilico.com

Insilico Medicine firmographics

Firmographics
Name
Insilico Medicine
Legal name
InSilico Medicine
Website
https://insilico.com
Company type
Public
Founded year
2014
Operating status
Ipo
Headcount range
251–500 employees
Ownership category
akta.pro rank

Insilico Medicine industry classification

Industry
Product category
AI Drug Discovery Software
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Laboratory Analytical Instruments (3826), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Generative chemistry platform
  • Target identification software
  • Clinical trial prediction
  • Biologics design platform

Where Insilico Medicine is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Insilico Medicine business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Software Licensing (Pharma.AI platform): Subscription and licensing revenue from Pharma.AI platform products (PandaOmics, Chemistry42, Generative Biologics, inClinico) licensed to pharmaceutical and biotech companies; more than 40 pharmaceutical companies use Insilico's technology.
  2. Drug Discovery Collaboration Deals (Upfront + Milestones): Large milestone-driven deals with pharma partners combining upfront payments (e.g., $115M from Eli Lilly, $80M from Exelixis), R&D funding, and milestone payments tied to development/regulatory/commercial progress (e.g., Eli Lilly up to $2.75B total, Sanofi up to $1.2B, SK Biopharmaceuticals up to $2.5B+, Servier $888M).
  3. Royalties on Net Sales: Tiered royalties on future net sales of products arising from collaborations, including single-digit royalties (e.g., SK Biopharmaceuticals deal) and tiered royalties (Eli Lilly deal).
  4. Co-development Revenue (Pipeline Programs): Revenue from co-developed programs with shared global rights (e.g., Hygtia Therapeutics 50/50 co-development of ISM8969), where Insilico is eligible for upfront and milestone payments as the program advances (up to $66M for Hygtia program).
  5. Grants and Non-dilutive Funding: Non-dilutive funding including the Bill & Melinda Gates Foundation grant ($700K+) for contraceptive design and other research grants.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise licensing — quote-based, milestone-driven
SubscriptionAnnualPharma.AI platform software — quote-based subscription
SubscriptionMulti-year contractMMAI Gym — 3-month training subscription

Go-to-market motion4 records

Insilico Medicine product offering

Product offering

Core offering

Insilico Medicine develops and commercializes Pharma.AI, an end-to-end generative AI software platform for drug discovery, with modules spanning biology (Biology42: PandaOmics, Generative Biologics, PreciousGPT), chemistry (Chemistry42), and clinical medicine (Medicine42: inClinico, Nach01), plus Science42: DORA LLM research assistant and MMAI Gym. The company also operates an internal pipeline of 30+ AI-discovered and AI-designed drug candidates and licenses/co-develops them with global pharmaceutical partners.

Product overview

Insilico Medicine is a global, clinical-stage, end-to-end generative AI-driven biotech offering a unified platform-plus-modules product architecture. The core platform is Pharma.AI, a commercially available end-to-end generative AI software suite spanning biology, chemistry, and clinical medicine, organized into three families: Biology42 (PandaOmics for AI target and biomarker discovery, with PandaOmics Box as an alternate packaging), Generative Biologics for biologics design, and PreciousGPT under the "Large Language of Life Models (LLLMs)" umbrella; Chemistry42 for generative small-molecule design, retrosynthesis, ADMET prediction, and molecule optimization; and Medicine42, which includes inClinico for AI-driven Phase II clinical trial outcome prediction and Nach01. Layered on top is the MMAI Gym, a service introduced in January 2026 for training and benchmarking large language models on drug discovery tasks, plus the newly announced LabClaw automation system. Complementing the platform, Insilico operates a fully automated robotics laboratory (Life Star, Suzhou) and an Abu Dhabi Generative AI and Quantum Computing R&D Center, and runs a diversified internal drug pipeline of more than 30 AI-discovered/AI-designed preclinical and clinical programs led by INS018_055/Rentosertib (TNIK inhibitor for IPF).

Differentiator

Problem solved

Functional benefit

Brands

  • Pharma.AI: End-to-end generative AI software platform for drug discovery, scientific research and sustainability, encompassing Biology42, Chemistry42, and Medicine42.
  • PandaOmics
  • Chemistry42
  • inClinico
  • Generative Biologics
  • Science42: DORA
  • MMAI Gym
  • PreciousGPT
  • Nach01

Products and services

  • Pharma.AI Suite
  • PandaOmics Generative AI software for therapeutic target and biomarker discovery with 20+ AI and bioinformatics models, transformer-based NLP knowledge graph of biomedical literature, and ChatPandaGPT natural-language querying. Sold to pharmaceutical and biotech researchers.
  • Chemistry42 Generative chemistry platform integrating 40+ generative models (including autoencoders and GANs) with computational and medicinal chemistry methods to generate and optimize drug-like small molecules; supports structure-based and ligand-based design with AlphaFold integration. Sold to pharmaceutical and biotech researchers.
  • Generative Biologics Generative AI platform module for designing therapeutic biologics including therapeutic proteins and antibody candidates, sold as part of the Pharma.AI suite.
  • inClinico Generative AI platform that uses a multimodal forecast (small-molecule chemical properties, transcriptomics, text, and clinical trial protocols) to predict Phase II to Phase III clinical trial transition probability. Sold to pharmaceutical and biotech customers.
  • Science42: DORA Draft Outline Research Assistant workflow built on Insilico's Science42 large language model platform, supporting AI-assisted scientific literature drafting, target discovery research, and pharmaceutical R&D workflows.
  • Nach01 Generative AI application under the Medicine42 suite of Pharma.AI, listed in the platform navigation.
  • PreciousGPT Large Language of Life Models (LLLMs) generative AI offering under the Pharma.AI umbrella, presented alongside other LLM-based tools.
  • MMAI Gym Multi-Modal AI Gym — a service/training platform for LLM developers that offers 3-month training subscriptions to improve model drug discovery fitness and access to CSI/BSI Pharmaceutical Super Intelligence models.
  • LabClaw Intelligent automation system intended to advance drug discovery from automation to autonomy, integrating with the Suzhou Life Star robotics laboratory and the broader MMAI Gym ecosystem.
  • INS018_055 / Rentosertib (ISM001-055) Lead clinical-stage small-molecule TNIK inhibitor designed by Insilico's generative AI for an AI-discovered target, for idiopathic pulmonary fibrosis (IPF) and kidney fibrosis; the first AI-discovered and AI-designed drug to enter Phase II trials. Available for licensing/co-development with pharmaceutical partners.

Companies that use Insilico Medicine

Customer profile

Ideal customer profiles3 records

Insilico Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature9 records

Insilico Medicine partnerships and signals

Strategic signal

Recent moves9 records

Expansion highlights7 records

Insilico Medicine competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput wet-lab biology with machine learning across target identification, hit generation, and translational research — directly comparable end-to-end generative-AI-for-drugs model with partnered pipeline.
  • Exscientia: Pioneer in AI-driven small-molecule design with a partnered pipeline (e.g., DSP-1181 with Sumitomo, BMS collaborations) using generative chemistry and active learning — directly comparable generative chemistry platform and pharma partnership GTM.
  • Schrödinger: Physics-based computational chemistry and AI-driven molecular simulation platform with both a software business (licensed to pharma/biotech) and an internal drug pipeline — closely comparable hybrid software-plus-pipeline business model.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company building on DeepMind's AlphaFold with partnered programs including a $3B+ collaboration with Novartis and a $1.7B Eli Lilly deal — directly comparable in scaling AI platform deals with Big Pharma.
  • XtalPi: AI-plus-robotics drug discovery company combining quantum physics, ML, and automated labs with a large pharma partnership base (e.g., Pfizer) — directly comparable as a Greater-China-based, end-to-end AI drug discovery platform with similar GTM.
  • BenevolentAI: AI-driven drug discovery company with target identification and clinical pipeline assets (e.g., baricitinib repurposing), using biomedical knowledge graphs and ML — directly comparable target-discovery-plus-platform GTM.

Emerging players

  • AbCellera Biologics: AI-enabled antibody discovery platform with pharma partnerships (e.g., Eli Lilly for COVID antibodies) and an internal biologics pipeline — comparable as a tech-forward biologics discovery company with similar pharma licensing GTM.
  • Relay Therapeutics: Precision medicine company using computational/motion-based drug design to develop targeted oncology therapies (e.g., RLY-4008) — comparable motion-based generative design approach applied to a focused clinical pipeline.
  • Generate:Biomedicines: Generative biology company (Flagship-founded) using ML to design de novo protein therapeutics including antibodies and peptides — directly comparable Generative Biologics-like capabilities to Insilico's biologics module.
  • Atomwise: AI small-molecule discovery company using convolutional neural networks for structure-based design with multi-target pharma partnerships (e.g., Sanofi, Bayer) — comparable AI drug discovery GTM via partnership deals with major pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Insilico Medicine social profiles

Digital presence

Insilico Medicine compliance and trust

Trust signal

Compliance2 records

Insilico Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Insilico Medicine leadership team

Management profile

Number of profiles

Profiles12 records

Insilico Medicine subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Insilico Medicine funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors40 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Insilico Medicine M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insilico Medicine

What does Insilico Medicine do?

Insilico Medicine develops and commercializes Pharma.AI, an end-to-end generative AI software platform for drug discovery, with modules spanning biology (Biology42: PandaOmics, Generative Biologics, PreciousGPT), chemistry (Chemistry42), and clinical medicine (Medicine42: inClinico, Nach01), plus Science42: DORA LLM research assistant and MMAI Gym. The company also operates an internal pipeline of 30+ AI-discovered and AI-designed drug candidates and licenses/co-develops them with global pharmaceutical partners.

Is Insilico Medicine a public or private company?

Insilico Medicine is a public company. It is classified as public and is currently ipo.

When was Insilico Medicine founded?

Insilico Medicine was founded in 2014. It employs 251 to 500 people.

Where is Insilico Medicine based?

Insilico Medicine is headquartered in Boston, United States, in the North America region.

How does Insilico Medicine make money?

Five revenue lines are on record. Software Licensing (Pharma.AI platform) is the primary driver. The others are drug Discovery Collaboration Deals (Upfront + Milestones), royalties on Net Sales, co-development Revenue (Pipeline Programs) and grants and Non-dilutive Funding.

Who are Insilico Medicine's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Exscientia, Schrödinger, Isomorphic Labs, XtalPi and BenevolentAI. Emerging players are AbCellera Biologics, Relay Therapeutics, Generate:Biomedicines and Atomwise.

Does Insilico Medicine have an API?

No public API is recorded for Insilico Medicine.

What industry is Insilico Medicine in?

Insilico Medicine's product category is AI Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
JiemianE-ink Intelligent: Completed the first human administration of the exploratory trial for the non-opioid analgesic candidate ISM9528.Insilico Medicine completed the first human dosing of ISM9528, a non-opioid analgesic candidate, on November 17. The exploratory trial in healthy volunteers assesses safety, tolerability, pharmacokinetics, and pharmacodynamics. The company may expand the trial after regulatory approval.ScienmagInsilico Medicine Showcases Generative AI Drug Discovery Across MajorInsilico Medicine executives will present AI-driven drug discovery and robotic lab automation at London and Dubai conferences in November 2026. The company's CEO and president will deliver keynote addresses at Jefferies, UBS, and Dubai Future Week, highlighting its closed-loop generative AI platform. The firm applies its Pharma.AI platform across fibrosis, oncology, and other therapeutic areas.ExameComo a IA pode reduzir o custo e o tempo para criar remédiosInsilico Medicine used AI to identify a target and design a compound for fibrosis in 18 months, leading to the experimental drug rentosertib. The average cost to bring a drug to market is estimated at $2.67 billion, with AI potentially cutting costs by improving phase 2 success rates.36krExclusive Interview with Ren Feng from Insilico Medicine: Insights on Young AI for Science (AI4S) Entrepreneurs' Ambition, Creativity & Future of AI-Driven Drug DiscoveryInsilico Medicine's Co-CEO Ren Feng discussed AI-driven drug discovery, noting the company's profitability in H1 2026 and 35 pipeline assets in the PCC stage. The disclosed BD cooperation value reached $11 billion, ranking first among domestic AI pharmaceutical enterprises. He emphasized that AI is integrated into decision-making, with 70-80% of code written by AI.ScienmagInsilico Medicine Announces Keynote Appearances at Global AI Drug DiscoveryInsilico Medicine announced keynote appearances at global AI drug discovery events in Shanghai, Nanchang, and Dubai in November 2026. The company nominated 11 preclinical candidates in the first 10 months of 2026, and Rentosertib entered Phase III trials for idiopathic pulmonary fibrosis.Longevity.TechnologyInsilico open-sources a longevity AI that keeps scoreInsilico Medicine has open-sourced Longevity Grok, an AI built with David Sinclair that turns personal health data into checkable N-of-1 experiments. The system files prediction cards committing to biomarker changes, then scores them against results, and users can pool data for research. The code is open for verification, but whether its forecasts prove bold enough to be wrong remains open.Longevity.TechnologyInsilico open-sources Longevity Grok personal longevity AIInsilico Medicine open-sourced Longevity Grok, a personal longevity AI developed with David Sinclair. The multi-agent system unifies health records, generates prediction cards, and forecasts risks, with default privacy via zero-trust architecture. It is available to Grok Bot users, and the codebase is open for inspection and modification.Business & FinancialAI For Drug Development And Discovery - Global Strategic Business Report 2026: Secure $18.1B By 2032 At 31.8% CAGR As Benevolentai, Biosymetrics, Healx And Insilico Medicine Disrupt Drug R&DThe global AI for drug development and discovery market was valued at $2.6 billion in 2025 and is projected to reach $18.1 billion by 2032, a 31.8% CAGR. Growth is driven by predictive molecular design, genomic data, and pressure to reduce R&D costs. The report also forecasts the target identification segment to reach $9.3 billion by 2032.Business & FinancialAI In Predictive Toxicology - Global Strategic Business Report 2026: Capture A $3.2 Billion Market By 2032 As Benevolentai, Insilico Medicine, Recursion Pharmaceuticals And Revvity Disrupt TestingThe global AI in predictive toxicology market was valued at US$584 million in 2025 and is projected to reach US$3.2 billion by 2032, a CAGR of 27.6%. The solutions segment is forecast to reach US$1.9 billion by 2032, while services grow at a 33.2% CAGR. Growth is driven by regulatory pressure, animal testing reduction, and precision medicine.MoomooInsilico Medicine (03696) repurchased 199,000 shares for HK$7.562 million on November 9.Insilico Medicine repurchased 199,000 shares on November 9, 2026, at a cost of HK$7.562 million. The company also issued 13,000 shares on the same day from the exercise of share options under its pre-IPO equity incentive plan.